| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 14.07. | AstraZeneca pays up to $1.5bn to license Dizal Pharma's lung cancer drug | ||
| 14.07. | Novartis and Chai Discovery collaborate on antibody identification | ||
| 14.07. | Cellares and Sonoma partner to automate cell therapy manufacturing | ||
| 13.07. | Germany approves healthcare costs overhaul despite significant pharma opposition | ||
| 13.07. | "Hub-and-spoke" drug manufacturing set to benefit from new FDA rule | ||
| 13.07. | Takeda and Indonesia partner on plasma-derived therapies | ||
| 13.07. | FDA approves MSD's Keytruda combinations for MIBC | ||
| 10.07. | Bayer banks €3bn in Apollo Global contraceptives division deal | ||
| 10.07. | Chinese biotech MindRank secures $52m to advance AI-designed oral GLP-1RA | ||
| 10.07. | Ipsen set to rival Botox after duo of Phase III migraine wins | ||
| 10.07. | Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar | ||
| 10.07. | Apertura and NIH institutes to test gene therapy for NPC1 | ||
| 09.07. | Moderna secures up to 24 million RSV vaccine dose contract with Europe | ||
| 09.07. | Sino and AstraZeneca sign licence agreement for TQC3721 | ||
| 09.07. | Evogene and Tel Aviv University launch drug discovery initiative | ||
| 08.07. | FDA cracks down on illegal ketamine sellers amid nearing 'psychedelic revolution' | ||
| 08.07. | Kalohexis confidentially files IPO to back obesity and cachexia portfolio | ||
| 08.07. | Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant | ||
| 08.07. | FDA grants rare paediatric designation to Vanda's CMT2S therapy | ||
| 08.07. | Biocytogen and Whitehawk partner to develop ADCs | ||
| 07.07. | Merck KGaA-backed Cyllene Therapeutics secures €33m for gene therapy pipeline | ||
| 07.07. | Vertex signs agreement to acquire Crinetics for $10bn | ||
| 07.07. | EC approves AbbVie's Tepkinly combination for follicular lymphoma | ||
| 06.07. | UK biotechs struggling to access finance as scale-up concerns grow | ||
| 06.07. | Novartis to acquire Myricx Bio in up to $1.5bn deal |